Taysha Gene Therapies (TSHA) Tops Q3 EPS by 19c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.64), $0.19 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• Bernstein SocGen on Oracle (ORCL): 'Next catalyst is FAM'